Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Coherus Bio (CHRS)

Coherus Bio (CHRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,355,991
  • Shares Outstanding, K 76,480
  • Annual Sales, $ 475,820 K
  • Annual Income, $ 132,240 K
  • 60-Month Beta 1.02
  • Price/Sales 2.82
  • Price/Cash Flow 8.37
  • Price/Book 7.69
Trade CHRS with:

Options Overview Details

View History
  • Implied Volatility 47.20%
  • Historical Volatility 45.92%
  • IV Percentile 13%
  • IV Rank 15.19%
  • IV High 101.64% on 02/18/21
  • IV Low 37.45% on 01/20/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 92
  • Volume Avg (30-Day) 173
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1,575
  • Open Int (30-Day) 1,622

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.24
  • Number of Estimates 1
  • High Estimate -0.24
  • Low Estimate -0.24
  • Prior Year 0.33
  • Growth Rate Est. (year over year) -172.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.66 +20.93%
on 09/07/21
17.89 -0.89%
on 09/24/21
+2.36 (+15.35%)
since 08/24/21
3-Month
12.21 +45.21%
on 08/06/21
17.89 -0.89%
on 09/24/21
+2.52 (+16.57%)
since 06/24/21
52-Week
12.21 +45.21%
on 08/06/21
22.22 -20.19%
on 01/27/21
-0.26 (-1.45%)
since 09/24/20

Most Recent Stories

More News
Positive Interim Results of CHOICE-01 Study Evaluating Junshi Biosciences and Coherus' Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer

Shanghai Junshi Biosciences Co., Ltd. ("Junshi Biosciences", HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. (Nasdaq: CHRS) announced the presentation today of positive interim results from the...

CHRS : 17.73 (+1.20%)
Positive Interim Results of CHOICE-01 Study Evaluating Coherus' and Junshi Biosciences' Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer

Coherus Biosciences, Inc. (Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. ("Junshi Biosciences", HKEX: 1877; SSE: 688180) announced the presentation today of positive interim results from the...

CHRS : 17.73 (+1.20%)
Coherus BioSciences Announces New Employment Inducement Grants

Coherus BioSciences, Inc. ("Coherus" or the "Company", Nasdaq: CHRS), today announced that effective Aug. 26, 2021, the compensation committee of the Company's board of directors granted options to purchase...

CHRS : 17.73 (+1.20%)
New Strong Sell Stocks for August 25th

BEEM, CHRS, KMDA, STIM and PHUN have been added to the Zacks Rank #5 (Strong Sell) List on August 25, 2021

CHRS : 17.73 (+1.20%)
KMDA : 5.35 (-0.37%)
STIM : 6.57 (-2.38%)
PHUN : 1.0100 (+1.21%)
BEEM : 28.41 (-6.67%)
Macy's, Kohl's rise; Toyota, Red Robin fall

NEW YORK (AP) — Stocks that traded heavily or had substantial price changes Thursday:

TM : 182.57 (-0.12%)
M : 23.70 (+2.29%)
INOV : 40.41 (+0.05%)
CHRS : 17.73 (+1.20%)
SNPS : 321.94 (-0.29%)
RRGB : 24.24 (+1.72%)
Coherus (CHRS), Junshi Announce Positive NSCLC Study Results

Coherus BioSciences (CHRS) and partner Junshi announce positive data from a late-stage study on toripalimab for the first-line treatment of NSCLC.

RHHBY : 46.0100 (-0.88%)
BMY : 60.23 (-0.66%)
MRK : 73.61 (+0.77%)
CHRS : 17.73 (+1.20%)
New Strong Sell Stocks for August 17th

ACCD, CHRS, ELVT, FLGT, and GSHD have been added to the Zacks Rank #5 (Strong Sell) List on August 17, 2021.

CHRS : 17.73 (+1.20%)
ELVT : 3.60 (+2.86%)
FLGT : 85.24 (-2.43%)
GSHD : 160.35 (-0.59%)
ACCD : 43.06 (-2.86%)
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -60.00% and 6.05%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

CHRS : 17.73 (+1.20%)
Coherus BioSciences Reports Second Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress

-1 line nasopharyngeal indication and 2/3 line indications to be concurrently submitted 3Q 2021

CHRS : 17.73 (+1.20%)
Coherus BioSciences to Report Second Quarter 2021 Financial Results on August 5th

Coherus BioSciences, Inc. ("Coherus", Nasdaq: CHRS), today announced that its second quarter 2021 financial results will be released after market close on Thursday, August 5, 2021. Starting at 5 p.m. ET,...

CHRS : 17.73 (+1.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid...

See More

Key Turning Points

3rd Resistance Point 18.57
2nd Resistance Point 18.23
1st Resistance Point 17.98
Last Price 17.73
1st Support Level 17.39
2nd Support Level 17.05
3rd Support Level 16.80

See More

52-Week High 22.22
Fibonacci 61.8% 18.39
Last Price 17.73
Fibonacci 50% 17.21
Fibonacci 38.2% 16.03
52-Week Low 12.21

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar